PIK3CA and breast cancer: Another study reported actionable ESR1 and PIK3CA alterations in 42% of BC patients using LB, including PIK3CA alterations in 27% (H1047×12%, E545×8%, E542K 5%), and ESR1 mutations in 24% (D538G, 11%; and Y537S, 8%).